patients, 24.8 and 28.6 months in the bi-weekly patients, and 25.2 and 33.0 months in the weekly patients ( fig. 1 ). Although the results did not reach statistical significance, the patients who received a tri-weekly course tended to show the most favorable outcomes. None of these patients died due to chemotherapy-related adverse events.
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In the TAX327 study, the median OS of the tri-weekly patients was 19.2 months, while that of the weekly patients was 17.8 months [1] . The SWOG9916 study showed that the median survival in the tri-weekly docetaxel was 17.5 months [3] . With regard to Japanese patients, Fukuta et al. [3] reported that the median OS was 22.0 months with a tri-weekly course. Our previous study showed the median OS of 20.1 months in patients who received tri-weekly docetaxel therapy [4] . Thus, triweekly docetaxel was recommended as a standard regimen for the treatment of CRPC. However, weekly or bi-weekly regimen has still been used clinically. There are a few studies assessing the efficacy of bi-weekly docetaxel courses, including one demonstrating the OS of 19.5 months [1, 5] . These studies concluded similar or even favorable prognosis between bi-weekly and triweekly regimens. In this study cohort, bi-weekly group Dear Editors:
Based on the results of large docetaxel phase 3 studies of the TAX327 and SWOG9916 studies, tri-weekly docetaxel is currently the standard therapeutic course for castration-resistant prostate cancer (CRPC) [1] . However, because Japanese patients have tended to show a higher rate of adverse effects, including febrile-neutropenia, various doses and patterns of docetaxel have been administered in Japan [2] . This study retrospectively assessed the effectiveness of 3 patterns of docetaxel chemotherapy, including tri-weekly, bi-weekly, and weekly therapy, in Yokohama City University Medical Center and 13 affiliated hospitals.
A total of 257 CRPC patients were analyzed in this study, of which 121 (47.1%), 72 (28.0%), and 64 (24.9%) patients received tri-weekly, bi-weekly, and weekly docetaxel chemotherapy with the doses of 55-75, 20-25, and 25 mg/m 2 , respectively. Most of the patients who received a bi-weekly docetaxel were also treated with estramustine. The criteria for selecting these therapies depended on the institution. The median and mean overall survival (OS) was 27.7 and 44.8 months in the tri-weekly Curr Urol 2016;10: [166] [167] [168] Different Patterns of Docetaxel Therapy in Japanese CRPC Patients 167 also received estramustine. Some benefit from estramustine might be included in this cohort. On the other hand, based on the TAX327 results showing a non-significant difference in OS between tri-weekly docetaxel therapy versus weekly docetaxel plus mitoxantrone, and therefore the former was recommended as the standard docetaxel treatment protocol. A sub-group analysis of TAX327 revealed that weekly docetaxel chemotherapy resulted in favorable OS compared with mitoxantrone in patients without liver or lung metastasis, a prostate specific antigen level of < 115 ng/ml at the time of administration, and poorer performance status [5] . Several studies in Japanese patients also showed a favorable outcome in those with a lower pretreatment prostate specific antigen level (e.g. more than100 vs. 50 ng/ml) [2, 3] .
In the current study, docetaxel chemotherapy with any of these 3 regimens was found to show better OS than the previous observations [1]. Although our results did not show statistical significance, tri-weekly docetaxel chemotherapy appeared to be superior to bi-weekly or weekly regimen.
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